Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 18

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 18
---
.50 |     | 12/17/2034             |

| (1) | The                                                                                            
 stock option vests as to 1/3 of the underlying shares on each of the first three anniversaries 
 of the vesting commencement date.                                                              |

| (2) | The                                                                                       
 stock options vests 100% of the underlying shares on the first anniversary of the vesting 
 commencement date.                                                                        |

| 11 |

<div align='center'>CORPORATE GOVERNANCE</div>

Director Independence

Under the Nasdaq listing standards, a majority of the members of our Board must qualify as “independent,” as affirmatively determined by the Board. The Board affirmatively determined that Dr. Lewis-Hall, Ms. Chiavacci Farley, and Mr. Fry are independent directors within the meaning of the applicable Nasdaq listing standards. Due to the resignations of Ms. McNealey and Ms. Charles, our Board is currently fixed at five members, consisting of a majority of independent members and all members of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee are independent directors under the applicable Nasdaq listing standards.

Meetings and Attendance

Our Board held 17 virtual or in-person meetings during fiscal year 2024. Each current director who served on the Board during fiscal year 2024 attended 100% of the total number of meetings held during fiscal year 2024 by our Board and committees of our Board of which such director was a member (during the period that the director served). We do not have a policy requiring our directors to attend our annual meetings of stockholders.

Board Leadership Structure and Role in Risk Oversight

The Board is responsible for the control and direction of the Company. We separate the positions of Chairperson of the Board and Chief Executive Officer of the Company. Dr. Lewis-Hall serves as the Chairperson of the Board and Dr. Regan serves as the Chief Executive Officer of the Company and as a member of the Board. The Board believes that this structure serves us well by maintaining a link between management, through Dr. Regan’s membership on the Board, and the non-executive directors led by Dr. Lewis-Hall in her role as a non-executive Chairperson.

While our executive officers are responsible for the day-to-day management of the material risks we face, one of the key functions of our Board is to conduct informed oversight of our risk management process. The Board does not anticipate having a standing risk management committee, but rather administers